EA at GB20 has been shown to ameliorate the changes in the MWT by altering c-Fos, 5-HT, 5-HT7R, CGRP, and cannabinoid 1 receptor (CB1R) expression in the descending pathway of migraine models [29–31, 40, 78]. Here, FOS is linked to migraine disorder.